Zyn US shipment volume in Q1 2026

Philip Morris International (PMI) is significantly expanding its U.S. Zyn manufacturing capacity. With an investment exceeding $800 million, these strategic efforts aim to meet increasing demand ^{[^]}. The company projects its total annual U.S. Zyn manufacturing capacity to reach 1.5 billion cans by early 2026 ^{[^]}. This expansion strategy involves establishing a new facility in Aurora, Colorado, and upgrading an existing plant in Owensboro, Kentucky ^{[^]}.

A new Aurora, Colorado facility forms a major part of this expansion. Representing a $600 million investment, this new manufacturing plant is expected to create 500 jobs ^{[^]}. It is slated to become operational in late 2025 and is designed to contribute 1 billion cans annually to PMI's overall capacity ^{[^]}.

The Owensboro, Kentucky facility also contributes significantly to capacity growth. PMI is investing an additional $232 million to expand its existing Zyn facility in Owensboro, Kentucky, following an initial $150 million investment ^{[^]}. This Kentucky expansion, anticipated to be completed in 2025, will add an annual capacity of 500 million cans and create 450 new jobs ^{[^]}. These combined initiatives are set to bring PMI's total U.S. manufacturing capacity for Zyn nicotine pouches to 1.5 billion cans annually by early 2026 ^{[^]}. Consequently, the targeted quarterly output for their U.S. facilities is projected to reach 375 million cans for Q1 2026 ^{[^]}.

No immediate federal flavor or concentration limits affect nicotine pouches. As of early 2026, no specific proposed federal regulations or U.S. Food and Drug Administration (FDA) marketing orders with scheduled implementation dates prior to March 2026 address flavor bans or nicotine concentration limits for nicotine pouches. While the FDA has proposed rules to reduce nicotine levels, these primarily target cigarettes and other combusted tobacco products, not nicotine pouches ^{[^]}. Similarly, draft guidance for premarket applications regarding flavored electronic nicotine delivery systems (ENDS) pertains to vapes, not nicotine pouches ^{[^]}.

FDA has authorized flavored pouches but now scrutinizes new applications. The FDA has previously authorized multiple nicotine pouch products for marketing, including flavored varieties, such as Zyn pouches ^{[^]}. Despite these existing authorizations, the regulatory environment for nicotine pouches is experiencing increased scrutiny. Reuters reported a slowdown in the FDA's 'fast-track scheme' for reviewing nicotine pouches due to mounting concerns about youth use and their potential to create new addicts ^{[^]}. This indicates a more cautious approach to future product authorizations, though no formal flavor bans or concentration limits with upcoming implementation dates for nicotine pouches have been identified.

Altria's 'on!' nicotine pouches achieved consistent market share growth in 2025. Throughout the year, 'on!' demonstrated quarter-over-quarter retail market share growth in major convenience store and gas station channels. Its share began at 6.9% in the first quarter ^{[^]}, increased to 7.5% in Q2 ^{[^]}, further grew to 8.1% in Q3 ^{[^]}, and concluded the year at 8.5% in the fourth quarter ^{[^]}. This performance reflected quarter-over-quarter growth rates of 8.7% for Q2 versus Q1, 8.0% for Q3 versus Q2, and 4.9% for Q4 versus Q3. Additionally, 'on!'s shipment volume expanded by 28% for the nine months ending September 30, 2025, compared to the prior year ^{[^]}.

Specific quarter-over-quarter data for BAT's 'Velo' was not available. While BAT's 'Velo' nicotine pouches experienced rapid growth and contributed to the overall market expansion in the U.S. during 2025 ^{[^]}, the research did not include precise quarter-over-quarter growth rates from Nielsen or IRI scanner data for its performance in key retail channels. The broader nicotine pouch category itself showed robust expansion throughout 2025, with brands such as 'on!' playing a significant role in this market growth ^{[^]}.

No explicit national distribution agreements for Zyn were found for the specified timeframe. Research indicates no explicit announcements of newly signed or expanded distribution agreements for Zyn with major national retail chains such as Walmart, Costco, or Kroger, specifically scheduled for initial 'channel fill' shipments during Q4 2025 or Q1 2026. While Zyn is reportedly available at Kroger as of March 2025 ^{[^]}, and the availability of Zyn pouches at Walmart has been discussed ^{[^]}, these provided sources do not detail new national distribution deals with these queried retailers for the specified future timeframe. Philip Morris International's (PMI) 2025 Fourth-Quarter & Full-Year Results press release ^{[^]}, a likely source for such strategic developments, did not contain explicit details regarding new national distribution agreements for the stated timeframe within the provided information.

Philip Morris International is expanding Zyn production significantly to meet future demand. Philip Morris International (PMI), the parent company of Zyn, is substantially increasing its production capacity with a new $600 million plant in Aurora, Colorado, which is slated to open in February 2026 ^{[^]}. This production expansion aims to boost supply for potential market growth. However, this information does not include announcements of specific new retail partnerships with Walmart, Costco, or Kroger for initial channel fill during Q4 2025 or Q1 2026.

PMI managed Zyn's trade inventory carefully to meet strong demand in 2025. In the first quarter of 2025, Philip Morris International reported robust Zyn sell-through rates in the U.S., reflecting strong consumer demand. A slight increase in distributor inventory levels early in the year was described as strategic stocking to meet accelerating demand and ensure product availability. Management characterized this as a healthy adjustment rather than an excessive build-up ^{[^]}. PMI explicitly focused on ensuring that trade inventory remained aligned with consumer purchasing trends, thereby actively avoiding overstocking ^{[^]}.

Strong Zyn sell-through persisted, maintaining optimized, lean trade inventory levels. Throughout the remainder of 2025, including Q2, Q3, and Q4, PMI consistently reiterated Zyn's strong sell-through rates, frequently highlighting market share gains and continued growth ^{[^]}. Management maintained that trade inventory levels were well-managed and optimized, demonstrating a close correlation with consumer demand and strong replenishment cycles ^{[^]}. There were no indications of an inventory glut or significant disconnect between shipments and sell-through, reinforcing a pattern of efficient supply chain management designed to keep pace with high consumption rates ^{[^]}. By the second half of 2025, commentary consistently described Zyn's trade inventory as lean or at optimal levels relative to the sustained high sell-through rates ^{[^]}. Shipments were directly responsive to accelerating consumer demand, indicating that product moved quickly off shelves ^{[^]}. Overall, PMI's statements throughout 2025 consistently pointed to a healthy, demand-driven pipeline where inventory at the distributor and retailer level was kept tight, aligning with strong sell-through rather than reflecting an inventory build-up ^{[^]}.

Catalyst analysis unavailable.